Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.

In the explorative subgroup analyses, the relative improvement in PFS in 2013–2017 versus 2008–2012 was numerically larger in patients aged under 65 years at diagnosis ( HR = 0.61) when compared with patients aged 65 + years ( HR = 0.79), in patients with HR−/HER2+ ( HR = 0.39) versus HR + /HER2 + disease (HR = 0.82) and in patients with multiple organs involved ( HR = 0.48) versus a single metastatic site ( HR = 0.80), although the tests for interaction did not reach statistical significance (Appendix Table 4 and Appendix Fig. 4 ).

also in 111,027 other papers